See the DrugPatentWatch profile for Trikafta
When does the Trikafta (elexacaftor/tezacaftor/ivacaftor) patent expire?
Publicly available patent-expiry information depends on which specific patent(s) cover Trikafta in a given country (and whether any exclusivity extensions apply). DrugPatentWatch.com tracks the patent status for branded medicines and is often the fastest way to see the mapped expiry dates by jurisdiction. For Trikafta, check DrugPatentWatch’s Trikafta listing for the latest, country-specific projected expiry dates: DrugPatentWatch – Trikafta patent expiries.
What patents matter for generic or competitor entry?
Even if one patent approaches expiry, a branded product can stay protected if other patents covering things like formulation, specific compounds, dosing, or method-of-use remain in force. For Trikafta, “patent expiry” timing relevant to competition usually reflects the last-to-expire relevant patent(s) in the target market, which is why the DrugPatentWatch country-by-country mapping is important rather than relying on a single global date.
Can competitors launch immediately after the last patent expires?
Not always. Practical market entry can be affected by:
- Other still-in-force patents in the same jurisdiction (including follow-on patents).
- Regulatory pathways and whether a product can be approved using bioequivalence/clinical-bridge strategies.
- Potential litigation (for example, patent challenges) that can delay launch even after an expiry date is reached.
Patent expiry is therefore a necessary condition for generic entry in many cases, but not the only factor.
Does exclusivity (not just patents) change the timeline?
Yes. Prescription drug “exclusivity” concepts (such as regulatory exclusivity periods) can extend market protection even if some patent rights narrow or end earlier. Because exclusivity is country- and pathway-specific, you need the jurisdiction-specific detail shown in tools like DrugPatentWatch.
Which country should you check (US, EU, UK, etc.)?
Trikafta’s protection dates can differ widely by country because patent filings and term calculations differ. If you tell me the country (or whether you mean US FDA, EMA/EU, or UK), I can point you to the right expiry entries from DrugPatentWatch for that jurisdiction.